Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination

Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination

We describe a case of second primary malignancy in a 65-year-old patient affected by polycythemia vera treated with the JAK 1/2 inhibitor ruxolitinib. The latter is recognized as a risk factor for the onset of non-melanoma skin cancers in many retrospective and perspective studies, but the concomita...

Full description

Bibliographic Details
Main Authors: Chiara Masucci, Mauro Passucci, Emilia Scalzulli, Ida Carmosino, Marcello Capriata, Alessandro Costa, Claudia Ielo, Maurizio Martelli, Massimo Breccia
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Oncology
Subjects:
avelumab
Merkel cell carcinoma
ruxolitinib
polycytemia vera
second malignancies
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1212638/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1212638/full

Similar Items